FINWIRES · TerminalLIVE
FINWIRES

$GL

12 stories mentioning GL

Every FINWIRES story that references GL, newest first.

Insider Trading

Globe Life Insider Sold Shares Worth $3,315,646, According to a Recent SEC Filing

Frank M Svoboda, Director, Co-Chairman & CEO, on June 11, 2026, sold 20,000 shares in Globe Life (GL) for $3,315,646. Following the Form 4 filing with the SEC, Svoboda has control over a total of 190,874 common shares of the company, with 54,020 shares held directly and 136,853 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/320335/000032033526000184/xslF345X05/form4.xmlPrice: $169.07, Change: $+2.31, Percent Change: +1.38%

$GL
Insider Trading

Globe Life Insider Sold Shares Worth $3,133,588, According to a Recent SEC Filing

Frank M Svoboda, Director, Co-Chairman & CEO, on May 22, 2026, sold 20,000 shares in Globe Life (GL) for $3,133,588. Following the Form 4 filing with the SEC, Svoboda has control over a total of 190,874 common shares of the company, with 54,020 shares held directly and 136,853 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/320335/000032033526000177/xslF345X05/form4.xmlPrice: $156.71, Change: $+0.43, Percent Change: +0.28%

$GL
Insider Trading

Globe Life Insider Sold Shares Worth $1,242,709, According to a Recent SEC Filing

Thomas Peter Kalmbach, Executive Vice President & CFO, on May 22, 2026, sold 7,936 shares in Globe Life (GL) for $1,242,709. Following the Form 4 filing with the SEC, Kalmbach has control over a total of 51,648 common shares of the company, with 50,496 shares held directly and 1,153 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/320335/000032033526000179/xslF345X05/form4.xmlPrice: $156.64, Change: $+0.36, Percent Change: +0.23%

$GL
Insider Trading

Globe Life Insider Sold Shares Worth $1,864,186, According to a Recent SEC Filing

Thomas Peter Kalmbach, Executive Vice President & CFO, on May 19, 2026, sold 11,903 shares in Globe Life (GL) for $1,864,186. Following the Form 4 filing with the SEC, Kalmbach has control over a total of 49,584 common shares of the company, with 48,432 shares held directly and 1,153 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/320335/000032033526000175/xslF345X05/form4.xmlPrice: $154.19, Change: $+4.32, Percent Change: +2.88%

$GL
Insider Trading

Globe Life Insider Sold Shares Worth $4,195,007, According to a Recent SEC Filing

Thomas Peter Kalmbach, Executive Vice President & CFO, on May 08, 2026, sold 27,427 shares in Globe Life (GL) for $4,195,007. Following the Form 4 filing with the SEC, Kalmbach has control over a total of 46,486 common shares of the company, with 45,335 shares held directly and 1,152 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/320335/000032033526000173/xslF345X05/form4.xml

$GL
Insider Trading

Globe Life Insider Sold Shares Worth $333,656, According to a Recent SEC Filing

Michael Shane Henrie, Senior Vice President & Chief Accounting Officer, on May 06, 2026, sold 2,150 shares in Globe Life (GL) for $333,656. Following the Form 4 filing with the SEC, Henrie has control over a total of 3,609 common shares of the company, with 3,449 shares held directly and 160 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/320335/000032033526000167/xslF345X05/form4.xmlPrice: $152.59, Change: $-1.80, Percent Change: -1.17%

$GL
Insider Trading

Globe Life Insider Sold Shares Worth $1,537,477, According to a Recent SEC Filing

Frank M Svoboda, Director, Co-Chairman & CEO, on May 01, 2026, sold 10,000 shares in Globe Life (GL) for $1,537,477. Following the Form 4 filing with the SEC, Svoboda has control over a total of 190,874 common shares of the company, with 54,020 shares held directly and 136,853 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/320335/000032033526000161/xslF345X05/form4.xmlPrice: $152.46, Change: $-0.26, Percent Change: -0.17%

$GL
Insider Trading

Globe Life Insider Sold Shares Worth $5,229,628, According to a Recent SEC Filing

Michael Clay Majors, Executive Vice President, Chief Strategy Officer, on April 24, 2026, sold 34,000 shares in Globe Life (GL) for $5,229,628. Following the Form 4 filing with the SEC, Majors has control over a total of 53,518 common shares of the company, with 53,518 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/320335/000032033526000147/xslF345X05/form4.xmlPrice: $152.68, Change: $+0.12, Percent Change: +0.08%

$GL
Insider Trading

Globe Life Insider Sold Shares Worth $555,168, According to a Recent SEC Filing

Michael Shane Henrie, Senior Vice President & Chief Accounting Officer, on April 24, 2026, sold 3,591 shares in Globe Life (GL) for $555,168. Following the Form 4 filing with the SEC, Henrie has control over a total of 3,607 common shares of the company, with 3,449 shares held directly and 158 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/320335/000032033526000146/xslF345X05/form4.xmlPrice: $152.69, Change: $+0.13, Percent Change: +0.08%

$GL
Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of Globe Life Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $12 to $177, valuing GL shares at 10.7x our 2027 operating EPS estimate of $16.55 (raised today by $0.35) and at 11.3x our 2026 EPS estimate of $15.65 (lifted by $0.65). Our target multiples compare to GL's five-year average forward multiple of 10.3x and a bifurcated peer average of 11x. Q1 operating EPS of $3.43 vs. $3.07 a year ago topped our $3.35 operating EPS estimate, on a 5.4% rise in revenues, in line with our forecast for a 3% to 8% rise. Premiums rose by 6% in Q1, reflecting a 3% rise in life premiums (in line with our 3% to 6% growth forecast) and a 13% rise in health premiums (above our 5% to 9% growth forecast). We expect a similar growth trajectory for premiums in 2026. We are also encouraged by Q1 new sales trends, including a 6% rise in life sales and a 58% surge in health sales. We think this positive sales momentum provides the shares, currently trading below peers at 9.8x our 2026 EPS estimate, with a catalyst.

$GL
Wire

BMO Capital Adjusts Globe Life PT to $150 From $148, Maintains Market Perform Rating

Globe Life (GL) has an average rating of overweight and mean price target of $173.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $153.49, Change: $-0.48, Percent Change: -0.31%

$GL
Research

Research Alert: Globe Life Q1 Eps Tops Our Expectations

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:GL posted Q1 2026 operating EPS of $3.43 vs. $3.07 prior year, beating our conservative $3.35 estimate but missing the $3.48 consensus view. Revenue rose 5.4%, in line with our 3% to 8% forecast, driven by 6% premium growth reflecting 3% life and 13% health premium increases. Strong sales momentum included 6% life sales growth and a 58% surge in health sales, with United American Division's health net sales exploding 122% Y/Y to $61.5M. Management raised 2026 operating EPS guidance to $15.40-$15.90 from $14.95-$15.65, suggesting confidence despite investment income pressures. We expect similar premium growth trajectories in 2026, projecting 2% to 6% life premium growth and 5% to 9% health premium increases. Agent count trends present mixed signals, with Liberty National and Family Heritage expanding 9% and 10% respectively, while American Income declined 4%. We are eager to hear management's perspective on middle-market consumer demand trends.

$GL